Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Benzodiazepines.

W E Haefely1

  • 1Pharmaceutical Research Department, F. Hoffmann-La Roche & Co., Ltd., Basle, Switzerland.

International Anesthesiology Clinics
|January 1, 1988
PubMed
Summary
This summary is machine-generated.

The GABAA receptor

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The multiplicity of actions of benzodiazepine receptor ligands.

Canadian journal of psychiatry. Revue canadienne de psychiatrie·1993
Same author

Evidence for a role of 5-HT1C receptors in the antiserotonergic properties of some antidepressant drugs.

European journal of pharmacology·1993
Same author

Effects of repeated mild stress and two antidepressant treatments on the behavioral response to 5HT1C receptor activation in rats.

Psychopharmacology·1993
Same author

Pharmacological characterization of benzodiazepine receptor ligands with intrinsic efficacies ranging from high to zero.

Psychopharmacology·1993
Same author

Aspects of benzodiazepine receptor structure and function with relevance to drug tolerance and dependence.

Biochemical Society symposium·1993
Same author

Behavioral profile of the 5HT1A receptor antagonist (S)-UH-301 in rodents and monkeys.

Brain research bulletin·1992
Same journal

Regional Anesthesia for Hip Fracture Surgery in Frail Adults: Primary Anesthetic and Perioperative Analgesic Approaches.

International anesthesiology clinics·2026
Same journal

The Transition of Total Joint Arthroplasty From Inpatient to Ambulatory Surgery Centers: Evolution, Evidence, and Implications.

International anesthesiology clinics·2026
Same journal

Patient Blood Management in Orthopedic Surgery.

International anesthesiology clinics·2026
Same journal

The Practitioner's Guide to Upper Extremity Nerve Blocks.

International anesthesiology clinics·2026
Same journal

Anesthetic Challenges and Strategies in Pediatric Spine Surgery.

International anesthesiology clinics·2026
Same journal

Development of a Preoperative Physical Frailty-associated Screening Process: A Quality Improvement Initiative.

International anesthesiology clinics·2026
See all related articles

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Pharmacology

Background:

  • GABA is the primary inhibitory neurotransmitter in the mammalian central nervous system (CNS).
  • GABAA receptors mediate major synaptic effects of GABA and belong to a family of receptor-operated ion channels.
  • These receptors possess allosteric modulatory sites, including the benzodiazepine receptor (BZR).

Purpose of the Study:

  • To elucidate the structure of the GABAA receptor.
  • To understand the molecular basis of BZR ligand interactions.
  • To enhance comprehension of neuronal receptor and neurotransmitter function.

Main Methods:

  • Structural identification of the GABAA receptor.
  • Pharmacological characterization of BZR ligands (agonists, inverse agonists, antagonists).

Related Experiment Videos

  • Analysis of ligand interactions at the BZR.

    • Main Results:

    • The structure of the GABAA receptor has been identified.
    • BZR ligands modulate GABAA receptor function: agonists yield anxiolytic/sedative effects, inverse agonists produce opposite effects.
    • BZR antagonists, like flumazenil, block these modulations.

    Conclusions:

    • The identification of GABAA receptor structure and BZR ligand interactions deepens understanding of CNS inhibitory neurotransmission.
    • BZR ligands offer therapeutic potential for conditions involving GABAergic system dysfunction.
    • Flumazenil represents a key therapeutic antagonist for BZR-mediated effects.